AXSOME THERAPEUT. DL-0001 WKN: A2AA7B ISIN: US05464T1043 Kürzel: AXSM Forum: Aktien Thema: Hauptdiskussion

oh sorry Olli war schneller.

Die FDA hat Axsome Therapeutics (NASDAQ: AXSM) AXS-12 für die Behandlung von Narkolepsie die Orphan Drug Designation erteilt. AXS-12 ist ein oraler, hochselektiver und potenter Noradrenalin-Wiederaufnahmehemmer. Das Unternehmen plant, im vierten Quartal eine Phase-2-Studie mit AXS-12 zu beginnen, deren Ergebnisse im ersten Halbjahr 2019 erwartet werden. Zu den Vorteilen des Orphan Drug Status in den USAist eine Marktexklusivität von sieben Jahren für die Indikation, wenn sie genehmigt wird. ✌

Bin nicht investiert.. Text lesen und mit Google ggf. übersetzen ✌️

Und das bedeutet was genau?

Axsome Therapeutics receives FDA Orphan Drug designation for AXS-12https://seekingalpha.com/news/3398012

Strohfeuer oder kommt morgen nochwas ;-)

THURSDAY (10/18): Axsome Therapeutics(NASDAQ:AXSM): R&D Day. Fall Dermatology Conference, Las Vegas (4 days). Foamix Pharmaceuticals(NASDAQ:FOMX): Phase 3 data on FMX101 for acne.

Axsome Therapeutics (NASDAQ:AXSM) creates Axsome Pain and Primary Care (Axsome PPC), a new business unit to house, manage, develop and enhance the value of Axsome’s non-CNS assets. The assets in Axsome PPC include the Company’s pain and primary care product candidates and related intellectual property. Axsome’s core CNS portfolio currently includes three differentiated, clinical-stage product candidates: AXS-05, AXS-07 and AXS-09. The assets in Axsome PPC include three Phase 3-stage product candidates. Two of the product candidates (AXS-06 and AXS-02) are being developed directly by Axsome, and one of the candidates (neridronate) is covered by Axsome’s intellectual property portfolio. These product candidates are being developed for five different indications including the signs and symptoms of osteoarthritis and rheumatoid arthritis, osteoporosis, the pain of knee osteoarthritis, chronic low back pain, and complex regional pain syndrome. The intellectual property of Axsome PPC includes 145 issued and more than 90 pending patents which provide protection as far as 2036. Of the current portfolio, 21 issued or allowed patents cover the use of neridronate for pain, including 10 patents that specifically cover CRPS, providing patent protection out to 2033. Shares are down 1% premarket.

& gibt nach... wie gesagt 18.10... vorher alles reine spekulation.

zieht an

Jetzt spannung bis 18.10. spekulationskäufe & dann + oder - 20% pharma eben ;-)

Axsome Therapeutics (NASDAQ:AXSM) will host an R&D Day with key opinion leaders on Thursday, October 18, in New York City. The event will highlight Alzheimer's disease candidate AXS-05. Preliminary data from the Phase 2/3 ADVANCE study should be available next quarter. AXS-05 is an orally available combination of bupropion and dextromethorphan. The role of bupropion, a norepinephrine and dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, is to enhance the bioavailability of dextromethorphan, an NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin and norepinephrine transporters.

Wie geht’s weiter hier? Tote Hose

NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC., on September 5, 2018 at 2:10 PM Eastern Time. The convention will be held at the St. Regis New York Hotel in New York, NY

Gestern mittag auf Seeking alpha

News?